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Background: Blood loss in hip and knee arthroplasties may necessitate allogeneic blood transfusions. Different
blood-saving measures (BSMs) were introduced to reduce these transfusions. Purpose of the present study was to
assess the frequency of BSM use, stratified by type and hospital setting of orthopaedic departments in the
Netherlands.
Methods: An internet-based questionnaire was sent to all heads of orthopaedic departments of Dutch hospitals
and private clinics (n = 99). Questions were asked on how often BSMs were used, reported on a 5-point Likert scale
(never, almost never, regularly, almost always, always). In addition there were questions about discontinuation of
anticoagulants preoperatively, the number of annually performed arthroplasties (size) and hospital setting.
Results: The survey was completed by 81 (82%) departments. BSMs used frequently (regularly, almost always,
always) were erythropoietine (EPO), with 55 (68%) departments being frequent users; acute normovolemic
hemodilution, used frequently in 26 (32%) departments; cell saver in 25 (31%) and postoperative drainage and re-
infusion in 56 (69%) departments. When compared by size, frequent EPO use was more common in large
departments (with 22 (88%) large departments being frequent users versus 13 (63%) small departments and 16
(55%) intermediate departments, p = 0.03). No differences by size or type were observed for other BSMs.
Conclusions: Compared with previous survey’s there is a tremendous increase in use of BSMs. EPO and autologous
blood salvage techniques are the most often used modalities. Costs might be saved if use of non-cost-effective
BSMs is stopped.
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Blood loss in elective total hip and knee arthroplasties
(THA and TKA) may necessitate allogeneic blood trans-
fusions. Yet, allogeneic blood transfusions carry the risk
of infections and noninfectious transfusion reactions
[1,2]. Concerns about these risks have led to the devel-
opment of blood-saving measures (BSMs) to reduce allo-
geneic blood transfusions. Many studies have been
performed to assess the effectiveness and to a lesser* Correspondence: l.vanbodegom-vos@lumc.nl
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reproduction in any medium, provided the orextent the cost-effectiveness of various BSMs [3-9]. Re-
sults of reviews on this subject show that the effective-
ness of the studied BSMs on allogeneic blood reduction
and the accompanying costs vary largely among studies
so that no firm conclusions on their use can be drawn
[3-9]. Besides, the available reviews on BSMs show that
the included studies had several limitations such as a
retrospective design, small patient numbers and poor
methodological quality [3-10]. In accordance with the
latter in 2011 the Dutch transfusion guideline indicated
that further research is needed to evaluate the cost-
effectiveness of BSMs [11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of orthopaedic departments








University medical centre 8 5 63
Teaching hospital 28 24 86
General hospital 54 46 85
Private clinic 9 6 67
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equate power was therefore performed recently to investi-
gate the cost-effectiveness of BSMs including preoperative
erythropoietine (EPO), perioperative cell saver, and a post-
operative drainage and re-infusion device (unwashed), in
elective primary THA and TKA, using a restrictive trans-
fusion trigger as described in the Dutch transfusion guide-
line [11]. It was shown that cell saver and postoperative
drainage and re-infusion devices did neither result in a de-
creased mean red blood cell use, nor in a decrease in the
proportion of transfused patients. Use of EPO showed a
significant decrease in the proportion of transfused pa-
tients, but costs were considered too high. Adherence to a
predefined uniform transfusion protocol was more than
95% in all participating hospitals. The conclusion of this
study was thus that these three BSMs were not cost-
effective in elective primary TKA and THA [12]. Annually,
TKA are performed in about 20.000 patients and THA in
about 26.000 patients [13], so that cost savings might be
considerable if BSMs are de-implemented [14].
Previous surveys showed an increase in the use of BSMs
between 1999 and 2007. A survey in 1999 showed that the
proportion of Dutch hospitals using pharmacologic BSMs
ranged from 0-2% and the use of non-pharmacologic
BSMs ranged from 10-24% [15]. A more recent survey in
2007 showed that EPO and postoperative drainage and
re-infusion were used in more than half of all Dutch
orthopaedic departments [16]. However, these surveys
did not distinguish between frequent and non-frequent
use, nor in what hospital setting (university-, teaching-,
general hospital or private clinic). This information is
needed to focus on activities to abolish non cost-effective
BSMs to those departments using BSMs frequently.
The aim of the present study was to assess the current
frequency of BSM use, stratified by hospital setting and
size of orthopaedic departments.
Methods
An internet-based questionnaire was sent in January 2012
to all heads of orthopaedic departments of hospitals and
private clinics within the Netherlands performing THA
and TKA (n = 99). Hospitals with multiple locations were
considered as a single hospital. Reminders were sent by
email 2 weeks and 4 weeks after the first invitation,
followed by a telephone call if necessary.
The study protocol has been presented to the Medical
Ethical Committee of the Leiden University Medical
Center. They declared ethical approval was not required
under Dutch national law (CME 11/104).
Questionnaire
The primary outcome measures of the questionnaire
were the frequency of use of the following 11 BSMs:
preoperative autologous donation, acute normovolemichemodilution, intraoperative cell saver, postoperative
drainage and re-infusion, EPO, tranexamic acid,
desmopressin, epsilon aminocaproic acid, fibrin glue,
platelet gel, and controlled hypotension. The frequency
of use was reported on a 5-point Likert scale (never, al-
most never, regularly, almost always, always). The sec-
ondary outcome measures were if, and how many days
prior to surgery, Coumadin derivatives, anti-platelet
drugs and NSAIDs were stopped. This was used to
assess whether there are associations between BSM use
and stopping anticoagulant drugs preoperatively, as
this might be part of blood management as well.
In addition, the questionnaire included questions
about department characteristics such as hospital setting
(university-, teaching-, general hospital or private clinic),
size of department (number of primary and revision
THA and TKA performed annually), and use of a re-
strictive transfusion protocol as described in the national
transfusion guideline (yes/no) [11].
Quality of care indicators
To test whether the transfusion rate in THA and TKA is
associated with the frequency of BSM use, the results of
this study were compared with self-reported allogeneic
blood transfusion rates that are publicly available for all
hospitals [17]. The number of patients with an ASA 1 or
ASA2 classification [18] undergoing a total THA or
TKA, and the number of these patients receiving an
allogeneic blood transfusion are reported by all Dutch
hospitals and private clinics.
Analysis
First, all responders were analyzed together on frequency
of BSM use to assess how often each BSM is used. Sub-
sequently they were stratified into non-frequent users
(never and almost never) and frequent users (regularly,
almost always and always). It was tested whether fre-
quent use varies among different hospital settings and
size of departments (number of arthroplasties divided
into tertiles). Differences between groups as well as asso-
ciations between frequent use of BSMs and the pre-
operative continuation or discontinuation of Coumadin
derivatives, anti-platelet drugs and NSAIDs were tested
Table 2 Frequency of BSM use in Dutch orthopaedic departments of hospitals and private clinics (n = 81)
Non-frequent Frequent
Never Almost never Total Regularly Almost always Always Total
Preoperative Autologous Donation (%) 64 (79) 14 (17) 78 (96) 1 (1) 2 (3) 0 3 (4)
Acute Normovolemic Hemodilution (%) 35 (43) 20 (25) 55 (68) 14 (17) 8 (10) 4 (5) 26 (32)
Perioperative cell saver (%) 30 (37) 26 (32) 56 (69) 20 (25) 1 (1) 4 (5) 25 (31)
Postoperative Drainage and Re-infusion (%) 17 (21) 8 (10) 25 (31) 16 (20) 15 (19) 25 (31) 56 (69)
Erythropoietin (%) 8 (10) 18 (22) 26 (32) 37 (46) 9 (11) 9 (11) 55 (68)
Tranexamic acid (%) 58 (72) 13 (16) 71 (88) 4 (5) 3 (4) 3 (4) 10 (12)
Desmopressin (%) 70 (86) 11 (14) 81 (100) 0 0 0 0
Epsilon aminocaproic acid (%) 69 (85) 12 (15) 81 (100) 0 0 0 0
Fibrin glue (%) 67 (83) 11 (14) 78 (96) 3 (4) 0 0 3 (4)
Platelet gel (%) 74 (91) 6 (7) 80 (99) 0 0 1 (1) 1 (1)
Controlled hypotension (%) 32 (40) 22 (27) 54 (67) 17 (21) 6 (7) 4 (5) 27 (33)
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than five, the Fisher-exact test was used. Unpaired t-tests
were used to test differences in transfusion rates.
For the analysis of the data the statistical software of
SPSS v17.0 was used. P-values ≤ 0.05 were considered
statistically significant in all analyses.
Results
81 (82%) orthopaedic departments completed the ques-
tionnaire. The response rates did not differ between differ-
ent hospital settings (χ2 = 0.74 with p = 0.86) (Table 1).
The median number of annually performed arthroplasties
among responding departments was 320 for THA (range
0–900) and 285 for TKA (range 35–900). In one clinic
only TKAs were performed.
Table 2 shows the frequency of BSM use among the
orthopaedic departments. Frequent use of preoperative
EPO was seen in 55 (68%) departments and frequent use
of autologous blood salvage was also common; with
acute normovolemic hemodilution used frequent by 26
(32%) departments, cell saver by 25 (31%) andTable 3 Differences in frequent BSM use by number of arthro
Small <439 (n = 27) Interme
Preoperative Autologous Donation (%) 1 (4) 0
Acute Normovolemic Hemodilution (%) 8 (30) 8 (28)
Perioperative cell saver (%) 9 (33) 6 (21)
Postoperative Drainage and Re-infusion (%) 18 (67) 20 (69)
Erythropoietin (%) 17 (63) 16 (55)
Tranexamic acid (%) 4 (15) 1 (3)
Desmopressin (%) 0 0
Epsilon aminocaproic acid (%) 0 0
Fibrin glue (%) 0 2 (7)
Platelet gel (%) 0 1 (3)
Controlled hypotension (%) 12 (44) 5 (21)postoperative drainage and re-infusion by 56 (69%) de-
partments. A few departments were frequent users of
pre-operative autologous donation (3 (4%)), pharmaco-
logic techniques other than EPO (range 0–10 (0-12%))
or the local techniques fibrin glue (3 (4%)) and platelet
gel (1 (1%)).
When the departments were stratified by size, it was
shown that frequent EPO use was more common in hos-
pitals with large numbers of arthroplasties (Table 3). No
significant differences were observed for the other BSMs.
When stratified by hospital setting no significant differ-
ences were observed, although there is a trend (p = 0.07)
that frequent EPO use was less common in university
medical centers. Other observed trends were that fre-
quent use of acute normovolemic hemodilution and
controlled hypotension were more common in teaching
hospitals and university medical centers (both p = 0.06)
(Table 4).
Considering the effect of anticoagulant drugs on the
frequency of BSM use, no effect was seen for the pre-
operative stopping of Coumadin derivatives and anti-plasties per year (hospital size)
diate 439–720 (n = 29) Large >720 (n = 25) Total (n = 81) P-value
2 (8) 3 (4) 0.30
10 (40) 26 (32) 0.59
10 (40) 25 (31) 0.29
18 (72) 56 (69) 0.92
22 (88) 55 (68) 0.03
5 (20) 10 (12) 0.16
0 0
0 0
1 (4) 3 (4) 0.39
0 1 (1) 0.40
9 (36) 27 (33) 0.16
Table 4 Differences in frequent BSM use by hospital setting
Private (n = 6) General (n = 46) Teaching (n = 24) University (n = 5) Total (n = 81) P-value
Preoperative Autologous Donation (%) 0 (0) 2 (4) 1 (4) 0 (0) 3 (4) 0.92
Acute Normovolemic Hemodilution (%) 0 (0) 12 (26) 11 (46) 3 (60) 26 (32) 0.06
Perioperative cell saver (%) 2 (33) 13 (28) 9 (38) 1 (20) 25 (31) 0.82
Postoperative Drainage and Re-infusion (%) 3 (50) 34 (74) 17 (71) 2 (40) 56 (69) 0.32
Erythropoietin (%) 3 (50) 33 (72) 18 (75) 1 (20) 55 (68) 0.07
Tranexamic acid (%) 1 (17) 4 (9) 4 (17) 1 (20) 10 (12) 0.72
Desmopressin (%) 0 0 0 0 0
Epsilon aminocaproic acid (%) 0 0 0 0 0
Fibrin glue (%) 0 2 (4) 1 (4) 0 3 (4) 0.92
Platelet gel (%) 0 0 1 (4) 0 1 (1) 0.49
Controlled hypotension (%) 2 (33) 10 (22) 12 (50) 3 (60) 27 (33) 0.06
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use was significantly more common in those hospitals that
stopped NSAIDS before surgery (82% vs 60%, χ2 = 3.98
P =0.05).
Seventy-three (90%) of the respondents stated to use
the national transfusion guideline [11]. Five departments
use a different locally designed algorithm (extended ver-
sion of the national transfusion guideline with advices
for the use of BSMs) [19], the other 3 departments
stated they do not have transfusions or they do not have
a guideline. No associations were found between trans-
fusion protocol and frequency of BSM use (data not
shown).
When self-reported transfusion rates were compared
with the frequency of BSM use, no differences in trans-
fusion rate between frequent or non-frequent BSM use
were found (Table 5).
Discussion
The present study showed that BSMs are frequently
used in TKA and THA, especially preoperative EPO useTable 5 Differences in percentage of transfused ASA 1 and AS
non-frequent BSM use
Non frequent use
Preoperative Autologous Donation (%) 5.6
Acute Normovolemic Hemodilution (%) 6.3
Perioperative cell saver (%) 5.4
Postoperative Drainage and Re-infusion (%) 4.7
Erythropoietin (%) 6.3
Tranexamic acid (%) 5.4
Desmopressin (%) 5.6
Epsilon aminocaproic acid (%) 5.6
Fibrin glue (%) 5.5
Platelet gel (%) 5.7
Controlled hypotension (%) 5.5and postoperative drainage and re-infusion. Frequent
EPO use is more common in hospitals with large num-
bers of arthroplasties, and a trend is found that frequent
EPO use is less common in university medical centers.
Frequent EPO use is significantly associated with stop-
ping of NSAIDs before surgery. No differences were ob-
served for the other BSMs.
A possible limitation of this study may be response
bias if frequency of BSM use differs between responders
and non-responders. Considering the high overall re-
sponse rate (82%) and the fact that response did not differ
per hospital setting, the effect of response bias is likely to
be limited.
A second limitation of this study is the use of the sub-
jective measure ‘number of BSMs used’. The use of this
measure assumes that the respondents in our survey, i.e.
the heads of orthopaedic departments of hospitals and
private clinics within the Netherlands performing THA
and TKA, have an adequate insight in the frequency of
BSM use. Within the scope of this study it was not pos-
sible to verify the reliability of their reporting. However,A 2 patients in hospitals reporting frequent and
Frequent use CI P-value
4.3 −4.28 to 7.02 0.63
4.2 −0.34 to 4.44 0.09
6.0 −3.07 to 2.00 0.67
6.0 −3.75 to 1.16 0.30
5.2 −1.34 to 3.46 0.38
7.6 −5.99 to 1.58 0.25
8.3 −8.41 to 2.83 0.33
0.0 −3.89 to 15.24 0.24
5.9 −2.81 to 2.02 0.74
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ized controlled trial of So-Osman et al. on the effective-
ness of EPO, perioperative cell saver and postoperative
drainage and re-infusion [12], the lack of an association
between transfusion rates and BSM use seems plausible.
Therefore the reported rates are likely to reflect actual
practice.
Another limitation is the number of participating
hospitals despite the high response rate in our survey
(82%). Therefore, we were able to only detect large robust
differences between frequent and non-frequent BSM users
and we might have overlooked minor differences (i.e. type
II error). However, it was not possible to further enlarge
our study population, since we have approached all Dutch
orthopaedic departments in The Netherlands for partici-
pation in our study.
A striking finding was that no association was found
between frequent BSM use and the self-reported transfu-
sion rates in ASA 1 and ASA 2 patients. This suggests
that BSM use does not influence the transfusion rate so
that these can be stopped without increasing this trans-
fusion rate. As ASA 3 patients with more co-morbidity
are more susceptible to receive allogeneic transfusions, it
remains possible that these patients may benefit from
BSMs. Given the restrictive transfusion policy used in
the Netherlands, which has led to a significant drop in
the number of blood transfusions [11,20], BSMs are
probably used more frequently than strictly necessary on
medical grounds.
The tremendous increase of BSM use over the past
13 years [7,8] in combination with the fact that EPO, cell
saver, and postoperative drainage and re-infusion are not
cost-effective [12] might give a huge cost reduction if
these BSMs are abolished in clinical practice. The question
remains why BSM use has increased so much over the
past years, and whether barriers exist that prevent doctors
to stop with these BSMs.
This survey is part of the ‘Leiden implementation study
of blood management in hip and knee arthroplasties’ (LIS-
BOA) which aims at designing an intervention to abolish
non-cost-effective BSMs including EPO, perioperative cell
saver and postoperative drainage and re-infusion from
clinical practice. The present survey provides the target
groups at which this intervention should be aimed. Fre-
quent EPO use for instance is seen more commonly in
departments with a large number of arthroplasties. The
trend that frequent EPO use is less common in university
medical centers is likely to be due to the fact that univer-
sity medical centers don’t perform large numbers of
arthroplasties annually. A possible explanation for this
finding might be that the logistics behind EPO administra-
tion are complicated and time consuming, which can
make it difficult for departments with smaller numbers of
arthroplasties to use EPO. The association betweenfrequent EPO use and stopping NSAIDs before surgery
may be explained by extra caution taken in these hospitals
to avoid blood transfusions. Interviews with involved med-
ical specialists in a later phase of the LISBOA study will
provide information about why departments choose for
BSMs and which barriers they experience to stop using
these BSMs. These results will also be taken into account
in designing an intervention to abandon non cost-effective
BSM use in clinical practice.Conclusions
In conclusion, this survey shows that BSMs are used fre-
quently in TKA and THA in Dutch orthopaedic practice
and its use has increased over the past years. The frequent
use of EPO was observed particularly in large hospitals.
Based on these findings, an intervention to abolish BSMs
will be developed to arrive at a cost-effective blood trans-
fusion policy. This will eventually lead to reduction of
costs in perioperative orthopaedic care.
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